Category: Blog

The essentials: On August 24, 2026, the FDA approved a new indication for Imaavy (nipocalimab-aahu, Johnson and Johnson) for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 years and older who are currently or previously treated with corticosteroids. This is the first time any therapy has been proven safe and effective specifically for wAIHA. No FDA-approved treatment for wAIHA has existed before this date. Imaavy was originally approved on April 29, 2025 for generalized myasthenia gravis (gMG). The wAIHA approval is its second indication. What wAIHA is: a rare, life-threatening autoimmune disease in which immunoglobulin G (IgG) autoantibodies attach to the surface of red blood cells and mark them for destruction, causing severe hemolytic anemia. The condition affects approximately 1 to 3 per 100,000 people per year. Prior standard of care relied on corticosteroids and non-specific immunosuppressants, which suppress the entire immune system rather than targeting the IgG autoantibodies driving the disease. What nipocalimab is: an immunoselective neonatal Fc receptor (FcRn) blocker. The FcRn receptor normally recycles IgG antibodies, extending their circulating half-life. By blocking FcRn, nipocalimab accelerates IgG degradation across all IgG subclasses, selectively reducing the pathogenic IgG autoantibodies that destroy red blood cells, while preserving B-cell function. The clinical basis: Phase 2/3 ENERGY trial (NCT04119050), multicenter, randomized, double-blind, placebo-controlled. 115 adults with wAIHA randomized approximately 1:1:1 to nipocalimab 30 mg/kg IV every 4 weeks, 15 mg/kg IV every 4 weeks, or placebo every 4 weeks. Approved dose: 30 mg/kg IV every 4 weeks. Primary endpoint: durable hemoglobin response, defined as achieving hemoglobin above 10 g/dL and an increase of at least 2 g/dL from baseline for at least 28 days without the need for rescue therapy. Result: approximately 3 times as many patients in the 30 mg/kg arm achieved durable hemoglobin response versus placebo by week 24; p value met statistical significance. Onset: mean hemoglobin improvement of at least 1 g/dL at week 1 (first post-baseline assessment) in the 30 mg/kg arm. Key secondary endpoint: FACIT-Fatigue score at week 24: mean difference 3.51 points (95% CI 0.64 to 6.39) in the 30 mg/kg arm versus placebo (higher scores indicate less fatigue). Corticosteroid reduction: 15% mean reduction from baseline CS dose in the nipocalimab arm versus 4% in placebo at week 24. Regulatory designations: Priority Review. Safety in ENERGY: consistent with the established safety profile from the gMG program.

This analysis was recently featured by Hemostasis Today in their weekly roundup of notable hematology posts. Read the feature: https://hemostasistoday.com/blog/10-posts-80305

Warm autoimmune hemolytic anemia does not announce itself with drama. It arrives the way most forms of anemia do: fatigue, pallor, shortness of breath with minimal exertion, a feeling of heaviness and exhaustion that does not resolve with rest. What distinguishes wAIHA from other anemias is its mechanism. The red blood cells are not being produced inadequately. The bone marrow is working. The problem is that the body’s own immune system has turned against its own red blood cells, producing IgG antibodies that bind to the cell surface and mark the cells for destruction in the spleen and liver. The red blood cells are being manufactured and destroyed in parallel, with destruction eventually outpacing production.

For decades, the therapeutic answer to wAIHA has been blunt: suppress the immune system broadly with corticosteroids, add more non-specific immunosuppressants if steroids fail, or remove the spleen to reduce the site of red cell destruction. These approaches work imperfectly. They carry substantial toxicity. They do not specifically target the IgG autoantibodies that are driving the disease. And until August 24, 2026, not a single one of them had been FDA-approved specifically for wAIHA. Every prescribing decision for wAIHA was being made off-label, without the regulatory framework of a purpose-built approval.

Imaavy (nipocalimab-aahu, Johnson and Johnson) changes that. The ENERGY trial demonstrated, in a randomized placebo-controlled study, that blocking the FcRn receptor reduces circulating IgG autoantibodies, raises hemoglobin to clinically meaningful levels, and reduces fatigue in patients with wAIHA whose disease had required corticosteroid management. The primary endpoint was not merely a laboratory improvement. It required hemoglobin above 10 g/dL, at least 2 g/dL above baseline, sustained for at least 28 days, without rescue therapy. Approximately three times as many nipocalimab patients met this stringent standard compared to placebo by week 24.

---

What Warm Autoimmune Hemolytic Anemia Is: The Immunology and the Clinical Burden

Autoimmune hemolytic anemia (AIHA) is classified by the temperature at which the responsible autoantibodies are most active. Warm AIHA, which accounts for approximately 70 to 80% of all AIHA cases, is driven by IgG autoantibodies that are most active at body temperature (37°C). Cold AIHA is driven by IgM antibodies active at lower temperatures.

In wAIHA, pathogenic IgG autoantibodies bind to antigens on the surface of red blood cells. The most commonly targeted antigens are components of the Rh blood group system. Once the red cell is coated with IgG, macrophages in the spleen and liver recognize the IgG Fc regions through Fc gamma receptors (FcγR) and engulf or partially consume the coated cells, removing them from circulation faster than the bone marrow can replace them. The resulting hemolytic anemia produces:

Anemia symptoms: Fatigue, weakness, pallor, dyspnea on exertion, and palpitations reflecting reduced oxygen-carrying capacity. Severe hemolysis can be life-threatening.

Hemolysis markers: Elevated lactate dehydrogenase (LDH), elevated indirect bilirubin (from heme degradation), low haptoglobin (which binds free hemoglobin released from destroyed red cells), and elevated reticulocytes (immature red cells reflecting bone marrow compensatory response).

Variable course: Approximately 1 to 3 new people per 100,000 are affected by wAIHA per year. The disease can be primary (idiopathic) or secondary to another condition including lymphoma, lupus, or other autoimmune diseases. It can be acute or chronic, with chronic relapsing disease representing the most clinically challenging form. Johnson & Johnson

The clinical burden of wAIHA is disproportionate to its apparent rarity. Fatigue in wAIHA is profound: patients with hemoglobin chronically in the 7 to 9 g/dL range have severely curtailed exercise tolerance, impaired cognitive function, and quality of life that matches or exceeds the burden of other chronic serious conditions. Hospitalizations for acute hemolytic crises, transfusions, and the side effects of chronic immunosuppression collectively produce a disease burden that is poorly captured by incidence numbers alone.

---

Why No Approved Treatment Has Existed: The Standard-of-Care Gap

The absence of an FDA-approved wAIHA treatment until August 2026 is not because the disease was unknown or because no effective approaches existed. It is because the drugs used to manage it, corticosteroids and immunosuppressants, are generic, widely available, and never received dedicated approval for wAIHA specifically. The clinical evidence base for these approaches is built from observational studies, case series, and small uncontrolled trials rather than the randomized placebo-controlled trials that form the basis of FDA approval.

The treatment algorithm prior to the Imaavy approval:

First line: corticosteroids (prednisone). Prednisone at 1 mg/kg/day produces response in approximately 70 to 80% of patients, but durable complete responses are achieved in only 20 to 30%. Most patients who respond to steroids relapse when steroids are tapered and require ongoing immunosuppression or additional therapy.

Second line options (all off-label): Rituximab (anti-CD20 antibody depleting B cells, the most commonly used second-line agent), splenectomy, azathioprine, mycophenolate mofetil, cyclophosphamide, and cyclosporine. Each of these approaches broadly suppresses immune function rather than specifically targeting the pathogenic IgG that drives the disease.

Previously, available treatment options only included corticosteroids and immunosuppressants — therapies that suppress the entire immune system without specifically targeting the IgG autoantibodies driving the disease. Lifesciencehistory

The clinical consequences of this non-specific immunosuppression include elevated infection risk, corticosteroid-induced hyperglycemia, osteoporosis, adrenal suppression, and the cumulative toxicity of long-term rituximab or other agents. For patients with chronic relapsing wAIHA requiring ongoing immunosuppression for years, this toxicity burden is substantial.

---

How Nipocalimab Works: FcRn Blockade and Selective IgG Reduction

Nipocalimab works through the neonatal Fc receptor (FcRn), a salvage receptor that plays a critical role in maintaining the circulating half-life of IgG antibodies. Understanding this mechanism requires understanding what FcRn normally does and what happens when it is blocked.

The FcRn salvage pathway

IgG antibodies, like all proteins, are naturally cleared from the circulation through degradation in lysosomes. In the absence of any protective mechanism, IgG would have a relatively short half-life. FcRn prevents this rapid clearance through a recycling mechanism: as IgG molecules are taken up by endothelial and immune cells through pinocytosis, they encounter FcRn in the acidic environment of early endosomes. The IgG Fc region binds to FcRn at acidic pH and the receptor-antibody complex is recycled back to the cell surface, where the neutral pH of the extracellular environment causes the IgG to dissociate and return to circulation. This recycling extends the normal half-life of IgG to approximately 21 days.

What FcRn blockade does

By binding to FcRn and blocking IgG from accessing the recycling pathway, nipocalimab prevents IgG from being rescued from lysosomal degradation. Without recycling, IgG antibodies, including the pathogenic IgG autoantibodies that drive wAIHA, are degraded at their natural rate without the FcRn salvage mechanism extending their half-life. Total IgG levels fall substantially across all IgG subclasses.

The pharmacological result in wAIHA: with fewer circulating pathogenic IgG autoantibodies available to bind red blood cell surfaces, fewer red cells are marked for destruction, hemolysis slows, hemoglobin levels rise, and the disease burden decreases.

The key pharmacological distinction from non-specific immunosuppressants: nipocalimab does not destroy B cells, does not suppress T cell function, and does not broadly impair immune surveillance. It selectively reduces IgG antibody levels through accelerated degradation. The manufacturer describes nipocalimab as immunoselective specifically to capture this distinction from broad immunosuppression. B-cell function is preserved, meaning the adaptive immune system’s long-term memory and other B-cell-mediated functions remain intact.

This same FcRn blocking mechanism is the basis of nipocalimab’s approved gMG indication: in myasthenia gravis, pathogenic IgG antibodies targeting the acetylcholine receptor (or MuSK) at the neuromuscular junction drive neuromuscular blockade, and reducing those IgG autoantibodies through FcRn blockade improves neuromuscular function.

---

The ENERGY Trial: Complete Data

Design

ENERGY (NCT04119050) is a multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study evaluating the efficacy and safety of nipocalimab compared with placebo, followed by an open-label extension period, in adults living with warm autoimmune hemolytic anemia. 115 adults were randomized approximately 1:1:1 to receive nipocalimab at two different doses or placebo: nipocalimab 30 mg/kg IV every 4 weeks (the approved dose), nipocalimab 15 mg/kg IV every 4 weeks, or placebo IV every 4 weeks. The trial required participants to be currently or previously treated with corticosteroids, consistent with the approved indication.

The primary endpoint was the stringent durable hemoglobin response: achieving hemoglobin above 10 g/dL and an increase of at least 2 g/dL from baseline for at least 28 consecutive days, without the need for rescue therapy during the 24-week treatment period.

This primary endpoint definition is clinically demanding in a way that deserves explicit acknowledgment. Requiring hemoglobin above 10 g/dL (not just any improvement), at least 2 g/dL above baseline (a meaningful clinical increment), sustained for at least 28 days (not a transient response), and without rescue therapy (confirming the improvement is drug-driven rather than rescue-supported) sets a threshold that reflects genuine clinical hemolysis control rather than a marginal laboratory change.

Efficacy results at week 24

Endpoint	Nipocalimab 30 mg/kg (approved dose)	Placebo	Result
Durable hemoglobin response (primary)	Approximately 3x more patients achieved durable Hgb response	Reference	p value met statistical significance
Mean hemoglobin change at week 1	Plus 1 g/dL	Reference	Rapid onset of effect at first post-baseline assessment
FACIT-Fatigue score at week 24 (key secondary)	Mean difference 3.51 points (95% CI 0.64 to 6.39) versus placebo	Reference	Descriptive per pre-specified statistical analysis plan
Mean CS dose reduction at week 24	15% reduction from baseline	4% reduction	Numerically higher with nipocalimab

Sources: J&J August 24, 2026 approval press release. ENERGY Phase 2/3 EHA 2026 data presentation. NCT04119050.

The approximately threefold improvement in durable hemoglobin response rate represents a clinically meaningful separation between nipocalimab and placebo on the most stringent available measure of hemolysis control. The week 1 hemoglobin improvement of 1 g/dL is notable: FcRn blockade reduces circulating IgG rapidly as the salvage recycling pathway is interrupted, and the speed of IgG reduction translates into measurable early hemoglobin improvement.

The FACIT-Fatigue improvement of 3.51 points at week 24 reflects the quality-of-life dimension of wAIHA that laboratory hemoglobin values alone do not capture. Fatigue is the most debilitating symptom reported by most wAIHA patients, and improvement in a validated patient-reported fatigue measure alongside hemoglobin improvement confirms that the laboratory benefit translates into patient-experienced benefit.

The corticosteroid reduction data (15% mean dose reduction with nipocalimab versus 4% with placebo at week 24) provides early evidence of the steroid-sparing potential of nipocalimab. Patients were required to taper corticosteroids when they achieved durable hemoglobin response (reducing by 10% of baseline dose every 2 weeks, provided hemoglobin did not decline by 1 g/dL or more). The greater dose reduction in the nipocalimab arm reflects the higher rate of hemoglobin response enabling steroid taper.

---

Imaavy’s Two-Indication Profile After August 2026

Nipocalimab is now approved for two distinct IgG-autoantibody-driven diseases, both of which share the mechanistic common ground of pathogenic IgG causing organ or tissue damage that is ameliorated by reducing IgG levels through FcRn blockade:

Indication	Disease mechanism	Approval date	Population
Generalized myasthenia gravis (gMG)	IgG autoantibodies against AChR or MuSK at neuromuscular junction	April 29, 2025	Adults
Warm autoimmune hemolytic anemia (wAIHA)	IgG autoantibodies against red blood cell surface antigens	August 24, 2026	Adults and pediatric patients aged 12 and older

The logic of both approvals is identical: the disease is driven by pathogenic IgG, reducing IgG through FcRn blockade reduces the pathogenic antibody driving the disease, and clinical benefit follows from reduced autoantibody-mediated tissue destruction. Nipocalimab is becoming a platform therapy for IgG-autoantibody-mediated diseases, analogous to how rituximab has become a platform therapy for B-cell-mediated conditions across multiple indications.

Johnson and Johnson has additional FcRn-mediated conditions in the nipocalimab clinical development pipeline, including hemolytic disease of the fetus and newborn (HDFN, where maternal IgG crosses the placenta and destroys fetal red blood cells), pemphigus vulgaris, and other IgG-mediated disorders. The breadth of the mechanistic applicability reflects the central role of FcRn in maintaining IgG levels across all autoimmune diseases driven by IgG autoantibodies.

---

Safety: What the ENERGY Data and Prescribing Information Cover

The safety profile of nipocalimab in the ENERGY wAIHA trial was consistent with the established safety profile from the gMG program, the most comprehensive nipocalimab safety database.

Class-level consideration: reduced IgG and infection risk. By reducing circulating IgG levels, FcRn blockade impairs one component of humoral immune defense. The most clinically relevant consequence is a potential increase in susceptibility to certain infections, particularly encapsulated bacteria and infections where IgG antibody titers provide primary immune protection. Patients should be counseled about infection risk, and patients with active serious infections should not initiate nipocalimab.

Immunization: Live vaccines should be avoided during nipocalimab treatment due to the potential for reduced vaccine efficacy from reduced IgG and the theoretical risk of infection from live attenuated organisms. Inactivated vaccines may be given but may produce lower antibody responses than in untreated patients.

IgG monitoring: Serum IgG levels should be monitored periodically during treatment. Clinically significant hypogammaglobulinemia (IgG below the lower limit of normal) may require dose interruption or discontinuation.

Pregnancy: Nipocalimab can cause fetal harm through IgG transport across the placenta (ironically, the same FcRn mechanism that nipocalimab blocks is responsible for normal maternal IgG transfer to the fetus during pregnancy). Women of reproductive potential should use effective contraception during treatment and for a specified period after the last dose.

Common adverse reactions in the ENERGY trial: consistent with the gMIg indication experience. The prescribing information will provide the complete adverse reaction listing from the ENERGY trial data.

---

Dosing and Administration

The approved dose for wAIHA is nipocalimab 30 mg/kg administered intravenously every 4 weeks (once monthly). This is the higher of the two doses tested in ENERGY and the dose that achieved statistical significance on the primary endpoint.

The IV infusion is administered over a specified infusion duration at qualified healthcare facilities. Unlike some autoimmune therapies where home administration is being explored, the current administration framework for nipocalimab requires a healthcare setting.

For pediatric patients aged 12 to 17: the indication covers this population based on the wAIHA approval; specific pediatric dosing considerations should be reviewed in the prescribing information, as pharmacokinetic differences between adults and adolescents may apply.

---

What This Means for Hematologists and wAIHA Patients

For hematologists

The wAIHA approval gives hematologists the first FDA-approved treatment specifically validated for this condition, with a mechanism that addresses the actual driver of the disease (pathogenic IgG) rather than broadly suppressing immune function.

The approved indication (patients currently or previously treated with corticosteroids) positions Imaavy as an option for patients beyond the initial steroid-only phase of management, which captures the population with the greatest unmet need: those with steroid-dependent or steroid-refractory disease who would otherwise cycle through non-specific immunosuppressants without a purpose-built approved option.

The corticosteroid reduction signal from ENERGY is clinically meaningful in a population for whom chronic steroid exposure is a significant morbidity concern. Whether nipocalimab can enable sustained steroid-free remission in a substantial proportion of patients is a question that longer-term follow-up from the ENERGY open-label extension will address.

As Dr. David Kuter, Director of the Center for Hematology, Massachusetts General Hospital, and a principal ENERGY investigator, noted: wAIHA is an underserved patient population that has long needed a treatment option specifically designed for this disease. This approval addresses a real clinical gap.

For patients with wAIHA

If you have been managing warm autoimmune hemolytic anemia with prednisone, rituximab, or other immunosuppressants and your disease has not been adequately controlled, or if the side effects of your current regimen have been burdensome, Imaavy is now an FDA-approved option to discuss with your hematologist.

The therapy requires monthly IV infusions at a healthcare facility. The clinical evidence shows rapid onset of hemoglobin improvement (beginning within the first week of treatment) and sustained improvement in both red blood cell counts and fatigue over the 24-week trial period.

The Hemolytic Anemia Initiative and the American Society of Hematology (hematology.org) maintain current resources on AIHA treatment and specialist referral for patients navigating this diagnosis.

For related HED coverage on IgG-autoantibody-mediated diseases and FcRn biology, note that Imaavy’s original gMG approval in April 2025 predates this session; the wAIHA approval is the drug’s second indication and the first to cover this specific disease. For coverage of other autoimmune hematologic conditions, see our post on Trutakna (atacicept-vymj) for IgA nephropathy, which covers the BAFF/APRIL cytokine axis that drives IgA production.

---

Sources

FDA approval announcement: FDA approves nipocalimab-aahu for warm autoimmune hemolytic anemia. FDA.gov. August 24, 2026.

J&J FDA approval press release: FDA approves IMAAVY (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA). jnj.com. August 24, 2026.

BioSpace press release: FDA approves IMAAVY (nipocalimab-aahu) as first-ever treatment for wAIHA. biospace.com. August 24, 2026.

Drugs.com approval news: FDA Approves Imaavy (nipocalimab-aahu) as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia. drugs.com. August 24, 2026.

BioPharm International (Priority Review, pediatric 12 and older population, first proven effective therapy context): FDA Approves J&J’s IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia. biopharminternational.com. August 2026.

LifeScienceHistory (full mechanism, FACIT-Fatigue data, 3x durable Hgb response rate, safety profile from gMG consistency): FDA approves J&J’s IMAAVY as first-ever treatment for wAIHA. lifesciencehistory.com. August 2026.

J&J sBLA submission press release (February 2026, primary endpoint definition, FACIT-Fatigue secondary endpoint, Dr. Fattizzo quote): Johnson and Johnson seeks FDA approval of IMAAVY as first-ever FDA-approved treatment for wAIHA. jnj.com. February 24, 2026.

J&J EHA 2026 data presentation (exact FACIT-Fatigue data, 15% CS dose reduction, week 1 Hgb data, 1:1:1 randomization, 115 adults): IMAAVY demonstrates durable hemoglobin response in pivotal Phase 2/3 study in wAIHA. jnj.com. June 11, 2026.

ENERGY trial registration: NCT04119050. ClinicalTrials.gov.

AIHA overview: Autoimmune Hemolytic Anemia. StatPearls. NCBI.

Imaavy prescribing information: IMAAVY (nipocalimab-aahu) Prescribing Information. Janssen/Johnson and Johnson. 2026.

Imaavy approval history: Imaavy FDA Approval History. drugs.com.

Patient resources: Hemolytic Anemia Initiative | American Society of Hematology patient resources | NORD (National Organization for Rare Disorders) AIHA resources | J&J Imaavy patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Imaavy (nipocalimab-aahu) reduces circulating IgG antibody levels through FcRn blockade; patients should be counseled about infection risk, the need to avoid live vaccines during treatment, and monitoring of IgG levels during therapy. The FACIT-Fatigue secondary endpoint at week 24 is considered descriptive per the pre-specified statistical analysis plan. Decisions about initiating Imaavy for wAIHA should be made in close collaboration with a board-certified hematologist experienced in the management of autoimmune hemolytic anemia.

The essentials: On August 5, 2026, the FDA approved mFLUSIVA (mRNA-1010, Moderna) for adults aged 50 years and older for the prevention of influenza caused by influenza A and B strains. mFLUSIVA is the first influenza vaccine built on messenger RNA technology to receive FDA approval in the United States. It is Moderna’s fourth FDA-approved product, joining Spikevax and mNEXSPIKE (COVID-19) and mResvia (RSV). The approval is age-stratified: full traditional approval for adults aged 50 to 64, based on clinical efficacy data from the Phase 3 FLUENT trial. Accelerated approval for adults aged 65 and older, based on immunogenicity data from a separate trial (NCT05827978), with a required postmarketing confirmatory efficacy trial in this age group. The FLUENT trial (NCT06602024): 40,805 adults aged 50 and older enrolled across 301 sites in 11 countries during the 2024 to 2025 influenza season. Randomized 1:1 to trivalent mFLUSIVA 37.5 mcg (12.5 mcg hemagglutinin mRNA per strain) or a standard-dose inactivated influenza vaccine comparator (Fluarix/Fluarix Tetra or equivalent). Primary endpoint: relative vaccine efficacy (rVE) against RT-PCR-confirmed, protocol-defined influenza-like illness caused by any influenza A or B strain. Results: influenza-like illness in 2.0% of mFLUSIVA recipients versus 2.8% of standard-dose comparator recipients. rVE 26.6% (95% CI 16.7% to 35.4%); met prespecified thresholds for noninferiority, superiority, and higher-level superiority (p less than 0.001). rVE in adults aged 65 and older: 27.4% (95% CI 12.1% to 40.0%). Published in the New England Journal of Medicine. NEJM doi:10.1056/NEJMoa2516491. Safety: solicited adverse reactions more frequent with mFLUSIVA than comparator. Injection-site pain: 65.8% versus 29.8%. Fatigue: 45.1% versus 20.3%. Headache: 37.8% versus 18.0%. Myalgia: 35.4% versus 11.6%. Most reactions mild to moderate and transient, resolving within 1 to 2 days. No myocarditis or pericarditis identified. Serious adverse events: 2.2% (mFLUSIVA) versus 1.9% (comparator); three mFLUSIVA-related serious events. No new safety concerns. Regulatory context: Moderna filed an initial BLA that the FDA refused to file in February 2026, citing incomplete information. A resubmission was accepted and the approval was granted on the PDUFA date of August 5, 2026. ACIP recommendation: pending; the Advisory Committee on Immunization Practices must issue a recommendation before federal vaccine programs (Medicare, Medicaid, VFC) can incorporate mFLUSIVA into routine vaccination schedules. This timing may affect coverage and availability for the 2026 to 2027 season. Commercial availability: Moderna expects mFLUSIVA to be available at select U.S. retailers within weeks of approval, with broader deployment for the 2026 to 2027 respiratory virus season. The vaccine contains three mRNA strains selected by the FDA for the 2026 to 2027 season: A/Missouri/11/2025 (H1N1), A/Michigan/105/2025 (H3N2-like), and B/Pennsylvania/19/2025.

Every year, influenza kills between 12,000 and 52,000 Americans and hospitalizes hundreds of thousands more. For the past 70 years, the response to that annual threat has been built on the same foundational technology: inactivated or live-attenuated influenza viruses grown in chicken eggs or cell culture, formulated into a shot that must be reformulated annually as circulating strains change and that provides variable protection depending on how accurately the season’s vaccine strains were predicted.

The mRNA platform changed the playbook for COVID-19. The same platform is now the basis of the first FDA-approved mRNA influenza vaccine.

mFLUSIVA (mRNA-1010, Moderna), approved August 5, 2026, is not just a technological curiosity. It is a vaccine that, in a 40,805-person Phase 3 trial covering the 2024 to 2025 influenza season, produced 26.6% fewer influenza illness episodes than a standard-dose inactivated flu vaccine, met all three prespecified superiority thresholds, and was published in the New England Journal of Medicine. It is more effective than the standard flu shot that most adults under 65 currently receive. It requires higher-frequency surveillance of adverse reactions, primarily due to more injection site discomfort and systemic symptoms, consistent with the mRNA vaccine class. And it opens a door that extends well beyond annual flu shots: a path to rapidly updated influenza vaccines, combination COVID-flu shots, and potentially pandemic-response influenza vaccines that could be designed and deployed in weeks rather than months.

This post covers what mFLUSIVA is and how it works, what the FLUENT trial showed and how to interpret the comparative efficacy data, the age-stratified approval structure and what the accelerated approval for adults 65 and older means practically, the safety profile and how it compares to existing flu vaccines, and what the ACIP recommendation question means for access this season.

---

What Influenza Is and Why the Annual Vaccine Is Imperfect

Influenza is a respiratory illness caused by influenza A and B viruses that circulate globally in seasonal epidemics, typically peaking in the Northern Hemisphere between October and March. Influenza viruses mutate rapidly through a process called antigenic drift, meaning the surface proteins of the virus, primarily hemagglutinin (HA) and neuraminidase (NA), change incrementally from season to season in ways that can reduce or eliminate the immunity generated by prior vaccination or infection.

This continuous evolution requires a new flu vaccine every year. The World Health Organization and the FDA recommend which strains to include in the coming season’s vaccine based on global surveillance of circulating strains. Manufacturers then produce the vaccine to match those recommendations. The process takes approximately 6 months from strain selection to distribution.

The limitation of egg-based and conventional cell-based influenza vaccines is that their efficacy is highly sensitive to how accurately the predicted strains match the strains that actually circulate. In seasons with good strain match, standard-dose vaccines produce approximately 40 to 60% efficacy. In poorly matched seasons, efficacy can fall to 20% or lower. The average annual efficacy of standard-dose flu vaccines in adults, across matched and mismatched seasons, has historically been 40 to 50%.

For adults 65 and older, the situation is more challenging. Aging immune systems produce lower antibody responses to standard-dose vaccines, leading to reduced protection in the population that accounts for the majority of influenza-associated hospitalizations and deaths. This is why higher-dose (Fluzone High-Dose) and adjuvanted (Fluad) influenza vaccines are specifically recommended for adults 65 and older: they stimulate stronger immune responses in older immune systems.

---

How mFLUSIVA Works: The mRNA Influenza Vaccine Mechanism

mFLUSIVA (mRNA-1010) uses the same lipid nanoparticle-encapsulated mRNA technology as Moderna’s COVID-19 vaccines. Rather than delivering inactivated virus particles or viral proteins directly, mFLUSIVA delivers messenger RNA sequences encoding the hemagglutinin proteins of the three target influenza strains. After injection, these mRNA sequences are taken up by cells at the injection site, which temporarily produce the encoded hemagglutinin proteins. The immune system recognizes these foreign proteins and mounts an adaptive immune response: generating antibodies against the HA proteins and establishing immunological memory.

The 2026 to 2027 mFLUSIVA formulation is trivalent, encoding HA from three strains:

• A/Missouri/11/2025 (H1N1 pdm09-like)
• A/Michigan/105/2025 (H3N2-like)
• B/Pennsylvania/19/2025 (B lineage)

Each strain component contains 12.5 mcg of hemagglutinin-encoding mRNA, for a total dose of 37.5 mcg per 0.38 mL injection.

Why mRNA vaccine manufacturing may improve speed and precision

The most significant potential advantage of the mRNA platform for influenza is not the approved product’s efficacy relative to existing vaccines. It is what the platform enables for future seasons:

Speed of strain update: Traditional egg-based flu vaccine manufacturing requires approximately 6 months from strain selection to distribution. mRNA sequences can be designed, synthesized, and scaled up substantially faster, potentially allowing vaccine composition updates later in the season cycle when circulating strains are better characterized.

No egg adaptation issues: Egg-based vaccines occasionally require adaptation of virus strains to grow efficiently in eggs, which can introduce mutations in the HA protein that reduce the match between the vaccine strain and circulating viruses. mRNA vaccines bypass egg production entirely, eliminating this source of mismatch.

Pandemic preparedness: An mRNA pandemic influenza vaccine could theoretically be designed within days of identifying a novel pandemic strain and manufactured at scale within weeks. This is the capability that makes the mFLUSIVA approval strategically important beyond its immediate clinical impact.

---

The FLUENT Trial: What the Data Shows

Design

FLUENT (NCT06602024) was a Phase 3, randomized, observer-blind, active-controlled, case-driven study enrolling 40,805 adults aged 50 years and older across 301 sites in 11 countries during the 2024 to 2025 Northern Hemisphere influenza season. Participants were randomized 1:1 to receive a single intramuscular dose of trivalent mFLUSIVA 37.5 mcg or a licensed standard-dose inactivated comparator (Fluarix, Fluarix Tetra, Influsplit Tetra, or Alpharix Tetra depending on country). Median follow-up was 181 days.

Influenza surveillance used twice-weekly electronic symptom prompts, with nasopharyngeal swabs collected within 72 hours of symptom onset and RT-PCR confirmation of influenza A or B. The primary endpoint was relative vaccine efficacy against the first episode of RT-PCR-confirmed, protocol-defined influenza-like illness caused by any influenza A or B strain beginning at least 14 days after vaccination through the end of the influenza season.

Efficacy results

Endpoint	mFLUSIVA	Standard-dose comparator	Result
Protocol-defined ILI (primary, per-protocol)	2.0% of participants	2.8% of participants	rVE 26.6% (95% CI 16.7% to 35.4%); met noninferiority, superiority, and higher-level superiority; p less than 0.001
rVE in adults aged 65 and older (subgroup)	—	—	27.4% (95% CI 12.1% to 40.0%)
Median follow-up	181 days	181 days	—
Participant demographics	Median age 64; 56.9% female; 82.6% White; 13.2% Black; 10.4% Hispanic/Latino	—	—

Source: Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. NEJM. 2026. doi:10.1056/NEJMoa2516491. FLUENT NCT06602024.

How to interpret the 26.6% relative vaccine efficacy number

The 26.6% relative vaccine efficacy means mFLUSIVA reduced the risk of RT-PCR-confirmed influenza-like illness by 26.6% compared to the standard-dose comparator vaccine. This is a superiority result over an active comparator, not over placebo. The standard-dose comparator was itself protecting participants from influenza, and mFLUSIVA provided an additional 26.6% reduction on top of that protection.

Absolute terms: 2.0% of mFLUSIVA recipients developed influenza illness versus 2.8% of standard-dose comparator recipients. The absolute risk reduction is 0.8 percentage points. In a population of 100 adults vaccinated with mFLUSIVA rather than a standard-dose vaccine, approximately 1 fewer person develops influenza during the season.

This framing matters for patient counseling. The trial was conducted during the 2024 to 2025 season, which may have had moderate strain match. In a high-match season, both vaccines perform better and the absolute risk difference may be smaller. In a low-match season, the mRNA vaccine’s composition precision may provide a larger relative advantage. The clinical significance of the 26.6% improvement over standard-dose will vary across seasons.

For adults 65 and older, the comparison that matters most is not mFLUSIVA versus standard-dose (which is not the recommended flu vaccine for this age group) but mFLUSIVA versus high-dose or adjuvanted vaccines. FLUENT was not powered to make this comparison directly; the accelerated approval for adults 65 and older reflects this gap.

---

The Two-Tier Approval Structure: What It Means for Adults 65 and Older

The age-stratified approval is the most practically important nuance of the mFLUSIVA label for clinicians.

Full approval for adults 50 to 64: Supported by the FLUENT Phase 3 clinical efficacy trial demonstrating statistically significant and clinically superior protection against influenza-like illness versus standard-dose vaccine. Standard-dose inactivated flu vaccines are the currently recommended option for this age group, and mFLUSIVA has now demonstrated clinical superiority over them.

Accelerated approval for adults 65 and older: This age group was included in FLUENT (n=19,260 participants aged 65 and older, rVE 27.4%), and the descriptive efficacy data are favorable. However, the FDA required the accelerated approval pathway for this age group based on a separate immunogenicity study (NCT05827978, n=2,992 adults aged 65 and older in the United States) that compared mFLUSIVA’s immune response against a high-dose inactivated influenza vaccine comparator. The accelerated approval for adults 65 and older is contingent on a required postmarketing confirmatory efficacy trial demonstrating clinical benefit versus the high-dose or adjuvanted comparators that are the current recommended standard for this age group.

Why does this matter clinically? Adults 65 and older are already recommended to receive high-dose (Fluzone High-Dose Quadrivalent) or adjuvanted (Fluad Quadrivalent) influenza vaccines rather than standard-dose vaccines, because those formulations provide stronger immune responses in the aging immune system. FLUENT compared mFLUSIVA against standard-dose, not against high-dose or adjuvanted vaccines. The accelerated approval structure acknowledges that clinical efficacy superiority versus the actual recommended standard of care for adults 65 and older has not yet been established. The confirmatory postmarketing trial will answer this question.

---

Safety: A Meaningful Increase in Reactogenicity

The safety profile of mFLUSIVA is characterized by higher rates of solicited local and systemic adverse reactions compared to standard-dose inactivated flu vaccines. This is a consistent feature of mRNA vaccines broadly, reflecting the more robust innate immune activation that the lipid nanoparticle mRNA delivery mechanism produces.

Adverse reaction	mFLUSIVA	Standard-dose comparator
Injection-site pain	65.8%	29.8%
Fatigue	45.1%	20.3%
Headache	37.8%	18.0%
Myalgia	35.4%	11.6%
Serious adverse events	2.2%	1.9%
Vaccine-related serious adverse events	3 events	2 events

Source: NEJM FLUENT publication. doi:10.1056/NEJMoa2516491.

Most reactions were mild to moderate and resolved within 1 to 2 days. Importantly, solicited adverse reaction rates were generally lower in adults 65 and older than in younger participants, which is consistent with the known pattern that older adults often experience less intense vaccine reactogenicity despite having weaker overall immune responses to vaccines.

No cases of myocarditis or pericarditis were identified across the full three-part clinical development program evaluating more than 4,200 participants. No new safety signals beyond the expected mRNA platform adverse reaction profile were identified.

The practical implication for patient counseling: adults receiving mFLUSIVA should be advised to expect a higher likelihood of injection site soreness, fatigue, headache, and muscle aches than they may have experienced with prior standard-dose flu vaccines. These reactions are evidence of immune activation, are expected, and resolve quickly. They do not indicate a problem with the vaccine.

---

The ACIP Recommendation Gap: What It Means for the 2026 to 2027 Season

FDA approval and ACIP recommendation are two distinct regulatory steps for vaccines. FDA approval authorizes a vaccine’s use in the United States. ACIP (Advisory Committee on Immunization Practices) recommendations, issued by the CDC, determine which vaccines are incorporated into federal vaccine programs including Medicare, Medicaid, the Vaccines for Children (VFC) program, and the immunization schedules used by most healthcare providers.

For a flu vaccine to be covered under Medicare Part B with no cost-sharing to patients, it must carry an ACIP recommendation. Without an ACIP recommendation, mFLUSIVA may be available commercially and administered to patients who choose it and whose insurance covers it, but it will not automatically be covered as a routine recommended vaccine at the zero cost-sharing level that applies to other ACIP-recommended flu vaccines.

ACIP meetings are scheduled periodically and must vote on new vaccines and vaccine recommendations. The timing of mFLUSIVA’s approval in early August 2026, with the flu season beginning in fall 2026, creates a potential window between approval and ACIP recommendation during which access will be limited for many patients.

Clinicians should be prepared for patient questions about whether mFLUSIVA is covered and available, and should be aware that the standard recommended flu vaccines remain the appropriate choice for patients who cannot access mFLUSIVA due to coverage or availability constraints. Receiving any recommended influenza vaccine is substantially better than delaying vaccination to wait for a specific formulation.

---

What mFLUSIVA Means for the Broader mRNA Vaccine Platform

The mFLUSIVA approval carries implications that extend beyond the 2026 to 2027 flu season:

mRNA-1083 (COVID-flu combination vaccine): Moderna has indicated that the mFLUSIVA approval resolves a key regulatory prerequisite for resubmitting its combination COVID-19 and influenza mRNA vaccine (mRNA-1083) in the United States. Establishing mFLUSIVA as an approved mRNA flu vaccine is part of the regulatory foundation for the combination product, which would allow simultaneous protection against both viruses with a single injection.

H5 pandemic influenza preparedness: Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI) have embedded the FLUENT Phase 3 data into a pandemic H5 influenza vaccine licensure plan. An mRNA H5 vaccine could be updated and manufactured far more rapidly than traditional egg-based H5 vaccines if an avian influenza pandemic emerged, providing a critical public health advantage.

Demonstrating mRNA flu platform validity: The approval confirms that the mRNA approach can produce clinically superior protection against influenza, not merely immune responses that might predict benefit. This is an important distinction: prior mRNA influenza Phase 2 studies showed strong immunogenicity; FLUENT is the first Phase 3 trial demonstrating actual efficacy superiority in a head-to-head comparison with an approved vaccine.

---

What This Means for Clinicians and Patients

For clinicians and vaccination providers

For adults aged 50 to 64, mFLUSIVA is now an FDA-approved flu vaccine option that demonstrated statistically significant superiority over standard-dose inactivated flu vaccines in a large Phase 3 trial. Standard-dose inactivated vaccines remain appropriate for this age group and are widely available; mFLUSIVA is an evidence-backed alternative when it becomes available in your market.

For adults aged 65 and older, the clinical picture is more nuanced. mFLUSIVA received accelerated approval in this age group and the FLUENT trial showed 27.4% relative efficacy versus standard-dose comparator. However, the recommended flu vaccines for adults 65 and older are high-dose or adjuvanted formulations. Whether mFLUSIVA is superior, inferior, or equivalent to Fluzone High-Dose or Fluad is not established from the available data. Until the confirmatory postmarketing efficacy trial comparing mFLUSIVA to high-dose/adjuvanted vaccines in adults 65 and older is completed, the established high-dose or adjuvanted vaccines remain the standard-of-care recommendation for this age group in guidelines.

ACIP recommendation timing will be the critical factor for broad deployment. Monitor ACIP meeting schedules and recommendations before the peak of the 2026 to 2027 flu season.

For patients

If you are 50 years of age or older and would like to receive the first mRNA-based flu vaccine, mFLUSIVA will become available at pharmacies and other vaccination locations during the fall 2026 flu season. The main practical difference from a standard flu shot you may notice is that injection site soreness, fatigue, headache, and muscle aches are more common with mFLUSIVA and may last 1 to 2 days.

If you are 65 or older: the high-dose and adjuvanted flu vaccines remain the standard recommendation for your age group. Whether mFLUSIVA is superior to those vaccines for people your age is an ongoing clinical question. Discuss the options with your provider.

The most important message remains unchanged regardless of which flu vaccine you choose: get vaccinated. Any approved influenza vaccine is substantially more protective than no vaccine, and the flu season waits for no one.

For related HED coverage on the mRNA vaccine platform and respiratory virus prevention, see our post on Leqembi Iqlik (lecanemab-irmb subcutaneous) receiving FDA approval as the first at-home disease-modifying Alzheimer’s therapy for a discussion of how delivery innovation changes treatment access, and our broader vaccine and public health coverage.

The CDC flu resources page (cdc.gov/flu) maintains current flu vaccine recommendations, ACIP schedules, and flu activity surveillance data. For 2026 to 2027 season flu shot availability in your area, the VaccineFinder tool at vaccines.gov is the most current locator.

---

Sources

FDA approval/Moderna press release: Moderna receives US FDA approval for influenza vaccine mFLUSIVA (mRNA-1010). Moderna. August 5, 2026.

FLUENT Phase 3 NEJM primary publication: Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. New England Journal of Medicine. 2026. doi:10.1056/NEJMoa2516491.

FLUENT trial registration: NCT06602024. ClinicalTrials.gov.

Immunogenicity trial registration (ages 65 and older, accelerated approval basis): NCT05827978. ClinicalTrials.gov.

HCPLive (full approval summary, trial design detail, ACIP context): mFLUSIVA Receives FDA Approval for Influenza in Adults 50 and Older. hcplive.com. August 2026.

PharmExec (rVE 26.6%, accelerated approval structure, geriatric burden data): FDA Approves Moderna’s mRNA-Based Flu Vaccine. pharmexec.com. August 2026.

Pharmacy Times (primary endpoints, safety profile full table, ACIP timing concern): FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine. pharmacytimes.com. August 2026.

Drug Topics (NCT05827978 enrollment detail, safety by age group, immunogenicity design): FDA Approves mFLUSIVA, First mRNA-Based Flu Vaccine. drugtopics.com. August 2026.

AJMC (refusal-to-file February 2026, resubmission timeline, Bancel quote): FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success. ajmc.com. August 2026.

TechTimes (mRNA-1083 combination vaccine context, pandemic H5 preparedness implication): mFLUSIVA Approved: FDA Clears mRNA Flu Shot, Unlocking Combo and Pandemic Vaccine Resubmission. techtimes.com. August 2026.

NBC News (general audience summary, first mRNA flu shot framing): FDA approves 1st mRNA flu shot, from Moderna. nbcnews.com. August 2026.

Applied Clinical Trials (trial design detail, reactogenicity exact numbers, swab methodology): Phase 3 Trial Finds Moderna’s mRNA-1010 Influenza Vaccine Outperformed Standard-Dose Vaccines. appliedclinicaltrialsonline.com. August 2026.

PMC FLUENT abstract: mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged 50 Years. PMC12792163.

CDC influenza overview: Influenza (Flu). CDC.

FDA flu vaccine information: Influenza Vaccines. FDA.

mFLUSIVA prescribing information: mFLUSIVA (mRNA-1010) Prescribing Information. Moderna. 2026.

Patient resources: CDC VaccineFinder / vaccines.gov: flu shot locator | CDC Flu Season Resources | ACIP recommendations | Moderna mFLUSIVA information

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. mFLUSIVA received accelerated approval for adults aged 65 and older based on immunogenicity data; clinical efficacy versus high-dose or adjuvanted influenza vaccines, which are the currently recommended standard for adults 65 and older, has not been established in a completed confirmatory trial. ACIP recommendation status, which affects vaccine coverage under federal programs including Medicare, was pending at time of publication. Vaccination decisions should be made in consultation with a qualified healthcare provider.